The Leona M. and Harry B. Helmsley Charitable Trust has awarded OHSU more than $4.3 million to support this work.
For many types of cancer, early detection can lead to better outcomes for patients. While scientists are developing new blood tests that analyze DNA to aid in earlier detection, these new technologies have limitations, including cost and sensitivity.
Bayer announced the acquisition of the global strategic imaging AI platform and solutions provider Blackford Analysis Ltd. The acquisition is part of Bayer's strategy to drive innovation in radiology, including the development and adoption of AI within the clinical workflow, with the goal to ultimately improve patient care and advance Bayer’s position in digital medical imaging.
Veradigm Inc. (NASDAQ: MDRX), formerly Allscripts Healthcare Solutions, Inc., announced an investment in Holmusk, a global behavioral health real-world evidence and data analytics company, as part of Holmusk's $45 million series B financing round. The round was led by Veradigm, with participation from current investors including Heritas Capital, Health Catalyst Capital, Novartis (dRx Capital), and Northwell Holdings, the venture investment arm of Northwell Health, as well as other previous investors.
This topic aims at supporting activities that are enabling or contributing to one or several impacts of destination 1 "Staying healthy in a rapidly changing society". To that end, proposals under this topic should aim for delivering results that are directed at, tailored towards and contributing to all of the following expected outcomes:
To make the EU the place where AI excellence thrives from the lab to the market, the European Union is setting up world-class Testing and Experimentation Facilities (TEFs) for AI.
Together with Member States, the Commission is co-funding the TEFs to support AI developers to bring trustworthy AI to the market more efficiently, and facilitate its uptake in Europe.